ArticleJournal of mood and anxiety disorders2026
Symptom benchmarks of improved quality of life among military veterans with PTSD.
Article in Journal of mood and anxiety disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To optimize treatment outcome and promote recovery, it is necessary to understand how clinical indicators of improvement translate into meaningful differences in the lives of individuals with posttraumatic stress disorder (PTSD). Prior research has suggested that treatment response alone is insufficient and that more substantial improvement is needed, but data are limited. This study addressed the gap through secondary analysis of a pragmatic comparative effectiveness trial of Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) in veterans. Methods: Participants were 597 male and female US military veterans who were randomized to receive CPT or PE. PTSD symptom change from pre- to posttreatment was categorized into four mutually exclusive categories: No Response, Response, Loss of Diagnosis, and Remission. Analyses compared each category to the prior one to identify the effect of attaining a higher benchmark on experiencing clinically meaningful improvements and good endpoints (no/little impairment in functioning or ≥70% on a QoL scale) on clinician-rated and self-reported measures. Results: Response was associated with improvement on most outcomes, but with a good endpoint on only one. Loss of Diagnosis added little benefit beyond response. Remission was associated with increased likelihood of meaningful improvement (OR=2.31-23.65, lowest Conclusions: Response without more substantial improvement following PTSD treatment is insufficient for helping patients achieve good QoL. Findings support the position that focusing on more than symptom change and response alone is necessary when setting treatment goals for individual patients and for evaluating treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.